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squamous cell carcinoma 
express components of the  
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aim: We have recently identified and characterized cancer stem cell (CSC) subpopulations 
within moderately differentiated buccal mucosal squamous cell carcinoma (MDBMSCC). 
We hypothesized that these CSCs express components of the renin–angiotensin system 
(RAS).
Methods: 3,3′-Diaminobenzidine (DAB) immunohistochemical (IHC) staining was 
performed on formalin-fixed paraffin-embedded MDBMSCC samples to investigate 
the expression of the components of the RAS: (pro)renin receptor (PRR), angiotensin 
converting enzyme (ACE), angiotensin II receptor 1 (ATIIR1), and angiotensin II receptor 
2 (ATIIR2). NanoString mRNA gene expression analysis and Western Blotting (WB) 
were performed on snap-frozen MDBMSCC samples to confirm gene expression and 
translation of these transcripts, respectively. Double immunofluorescent (IF) IHC staining 
of these components of the RAS with the embryonic stem cell markers OCT4 or SALL4 
was performed to demonstrate their localization in relation to the CSC subpopulations 
within MDBMSCC.
results: DAB IHC staining demonstrated expression of PRR, ACE, ATIIR1, and ATIIR2 
in MDBMSCC. IF IHC staining showed that PRR was expressed by the CSC subpop-
ulations within the tumor nests, the peri-tumoral stroma, and the endothelium of the 
microvessels within the peri-tumoral stroma. ATIIR1 and ATIIR2 were localized to the 
CSC subpopulations within the tumor nests and the peri-tumoral stroma, while ACE was 
localized to the endothelium of the microvessels within the peri-tumoral stroma. WB and 
NanoString analyses confirmed protein expression and transcription activation of PRR, 
ACE, and ATIIR1, but not of ATIIR2, respectively.
conclusion: Our novel findings of the presence and localization of PRR, ACE, ATIIR1, 
and potentially ATIIR2 to the CSC subpopulations within MDBMSCC suggest CSC as a 
therapeutic target by modulation of the RAS.
Keywords: buccal mucosa, squamous cell carcinoma, cancer, renin–angiotensin system, cancer stem cells, head 
and neck, oral cavity
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inTrODUcTiOn
Oral cavity cancer is the sixth most common cancer globally 
(1, 2) with more than 90% being squamous cell carcinoma (SCC) 
(2, 3). Oral cavity SCC (OCSCC) arises from the squamous 
epithelium of the lips, oral tongue, floor of mouth, hard palate, 
buccal mucosa, maxillary and mandibular alveolus, and the ret-
romolar trigone (1, 4). Predisposing factors for BMSCC include 
tobacco use, alcohol abuse, and betel leaf chewing (5). BMSCC 
is most prevalent in South East Asia and Southern Asia due to 
the habitual use of betel quid and betel leaf chewing (2, 4), more 
commonly in men (2).
Current treatment for BMSCC involves surgery, often with 
postoperative radiotherapy (RT), and sometimes chemotherapy 
(ChT) (2). Despite advances in treatment, 5-year survival for 
BMSCC remains 50–58%, and the overall survival has only 
increased by 5% in the past 20 years (1, 4, 6). This poor prognosis 
is partly due to late presentation with advanced loco-regional dis-
ease and less commonly metastasis to the bone, brain, or liver (5).
Cancer stem cells (CSCs) have been demonstrated in many 
types of cancers and have been proposed to be the origin of these 
cancers, including BMSCC (7). CSCs are suggested to play a 
crucial role in carcinogenesis with their ability for self-renewal 
and differentiation into multiple lineages through symmetric and 
asymmetric division, giving rise to diverse cell populations (7).
Although the origin of CSCs remains unclear (8), they are 
distinguished from the majority of the cancer cell population 
by their expression of CSC markers (9). Overexpression of CSC 
markers has been associated with increased tumor size, local 
invasion, and metastasis (10, 11). Increased expression of CSC 
markers has also been associated with worse prognosis (12–14), 
treatment resistance, and higher risk of loco-regional recurrence 
and distant metastasis following RT and ChT (15).
We have recently demonstrated the presence, within mod-
erately differentiated buccal mucosal squamous cell carcinoma 
(MDBMSCC), of an EMA+/SOX2+/SALL4+/OCT4+/pSTAT3+/
NANOG+ CSC subpopulation within the tumor nests; as 
well as two separate peri-tumoral stromal populations one 
expressing EMA−/SOX2+/OCT4+/pSTAT3+/NANOG+ and 
another expressing EMA−/CD34+/SOX2+/OCT4+/pSTAT3+/
NANOG+ localized to the endothelium of the microvessels (16). 
Intriguingly, this unique expression pattern parallels our recent 
findings in moderately differentiated oral tongue SCC (OTSCC) 
(17). The renin–angiotensin system (RAS) is a hormonal system 
that is classically associated with blood pressure regulation (18, 
19). A key component of the RAS is angiotensinogen (ANG) 
that is physiologically released from the liver into the circulation 
(20). ANG is converted to angiotensin I (ATI) by renin – the 
active form of the proenzyme, pro-renin (18, 21). The receptor 
for both renin and its proenzyme is known as the (pro)renin 
receptor (PRR) (22). ATI is then converted to angiotensin II 
(ATII) by angiotensin converting enzyme (ACE) (18). The 
effects of the vasoactive ATII are mediated through its receptors, 
angiotensin II receptor 1 (ATIIR1) and angiotensin II receptor 
2 (ATIIR2) (18).
We have previously demonstrated the role of stem cells in the 
biology of infantile hemangioma (IH) putatively regulated by the 
RAS (23, 24). This, coupled with recent publications, suggesting 
a role for the RAS in cancer growth (18), with components of 
the RAS: ACE, ATIIR1, and ATIIR2, being demonstrated in 
areas of cancer (25), led to the notion of RAS playing a role in 
tumor angiogenesis and tumor cell proliferation (25), both being 
determinants of tumor growth and metastasis. This suggests the 
RAS as a potential therapeutic target for cancer (18). Despite 
the proposed role of the RAS in carcinogenesis (18), there are 
currently no publications showing the presence of the RAS in 
BMSCC.
In this study, we investigated the expression of the com-
ponents of the RAS: PRR, ACE, ATIIR1, and ATIIR2 within 
MDBMSCC using immunohistochemical (IHC) staining, 
Western Blotting (WB), and NanoString gene expression 
analysis. We also investigated the localization of these proteins 
in relation to the CSC subpopulations we have identified within 
this tumor (16).
MaTerials anD MeThODs
Tissue samples
Moderately differentiated buccal mucosal squamous cell carci-
noma (MDBMSCC) specimens from one female and five male 
patients, aged 38–80 years (mean 59.3 years), sourced from the 
Gillies McIndoe Research Institute’s Tissue Bank, were used for 
this study, which was approved by the Central Regional Health 
and Disability Ethics Committee (ref. no. 12/CEN/74).
histochemical and immunohistochemical 
staining
Hematoxylin and eosin (H&E) staining was used to confirm the 
appropriate histological grade and to identify areas of MDBMSCC 
within the tissue sections by an anatomical pathologist (HDB). 
3,3′-diaminobenzidine (DAB) IHC staining was performed on 
4-μm thick formalin-fixed paraffin-embedded sections of six 
MDBMSCC samples using primary antibodies for SOX2 (1:500; 
cat# PA1-094, Thermo Fisher Scientific, Waltham, MA, USA), 
OCT4 (1:30; cat# MRQ-10, Cell Marque, Rocklin, CA, USA), 
epithelial membrane antigen (EMA, ready-to-use; cat# PA0212, 
Leica), CD34 (ready-to-use; cat# PA0212, Leica), PRR (1:2000; 
cat# ab40790, Abcam, Cambridge, MA, USA), ACE (1:100; cat# 
MCA2054, AbD Serotec, Raleigh, NC, USA), ATIIR1 (1:30; cat# 
ab9391, Abcam), and ATIIR2 (1:2000; cat# NBP1-77368, Novus 
Biologicals, Littleton, CO, USA). All slides were mounted in 
Surgipath Micromount (Leica).
To determine co-expression of the proteins, immuno-
fluorescent (IF) IHC staining was performed on two samples of 
MDBMSCC from the original cohort of six patients used for DAB 
IHC staining, utilizing a combination of Vectafluor Excel anti-
mouse 488 (ready-to-use; cat# VEDK2488, Vector Laboratories, 
Burlingame, CA, USA) and Alexa Fluor anti-rabbit 594 (1:500; 
cat# A21207, Life Technologies, Carlsbad, CA, USA) to detect 
combinations that included OCT4 and SALL4 with PRR, ACE, 
ATIIR1, and ATIIR2. All IF IHC-stained slides were mounted in 
Vecta Shield Hardset mounting medium with 4′,6′-diamidino-
2-phenylindole (Vector Laboratories).
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Positive human control tissues used for primary antibodies 
were placenta for PRR; liver for ACE, ATIIR1, and ATIIR2; 
and seminoma for OCT4 and SALL4. A negative MDBMSCC 
control sample was also prepared by omitting the primary 
antibodies.
All antibodies were diluted with Bond primary antibody 
diluent (cat# AR9352, Leica), and all DAB and IF IHC staining 
was carried out on the Leica Bond Rx autostainer as previously 
described (26).
nanostring gene analysis
Five snap-frozen MDBMSCC samples from the original cohort 
of patients used for DAB IHC staining were utilized for isola-
tion of total RNA for NanoString nCounter™ Gene Expression 
Assay (NanoString Technologies, Seattle, WA, USA). Extraction 
of RNA from tissues was performed using RNeasy Mini Kit 
(Qiagen, Hilden, Germany). RNA was quantitated by Qubit® 2.0 
Fluorometer (Life Technologies) and subjected to NanoString 
nCounter™ gene expression assay completed by New Zealand 
Genomics Ltd (Dunedin, NZ), according to the manufacturer’s 
protocol. Probes for the genes encoding for PRR (ATP6AP2, 
NM_005765.2), ACE (NM_000789.2), ATIIR1 (AGTR1, 
NM_000685.3), ATIIR2 (AGTR2, NM_000686.3), and the 
housekeeping gene GUSB (NM_000181.1) were designed and 
synthesized by NanoString Technologies. Raw data were analyzed 
by nSolver™ software (NanoString Technologies) using standard 
settings. Results were normalized against the housekeeping gene 
and graphed using Excel (Microsoft Office 2013).
Western Blotting
Total protein was extracted from five MDBMSCC specimens 
by homogenization in ice-cold RIPA buffer (Sigma–Aldrich, 
St Louis, MA, USA) containing 10mM dithiothreitol (DTT) 
(Sigma–Aldrich) and 1× HALT protease and phosphatase 
inhibitor cocktail (Thermo Fisher Scientific). Solubilized 
proteins were precipitated for 1  h at −20°C (ProteoExtract® 
Protein Precipitation Kit, Merck Millipore, Billerica, MA, 
USA) and then re-suspended overnight in 1× Laemmli sample 
buffer (Bio-Rad, Hercules, CA, USA) containing 10mM DTT. 
Equal amounts of protein extracts were heated in sample buffer 
and then separated by Bolt™ 4–12% Bis-Tris Plus gel (cat# 
NW04120, Invitrogen, Carlsbad, CA, USA) electrophoresis. 
Separated proteins were then transferred to PVDF membrane 
(cat# IB24001, Life Technologies), which were then blocked 
in TBS containing 0.1% Tween-20 and 2% skim-milk powder 
for 90  min at 4°C. The membranes were subsequently probed 
using the following primary antibodies: PRR (1:500; cat# 
HPA003156, Sigma–Aldrich), ACE (1:200; cat# sc-12184, 
Santa Cruz Biotechnology, Dallas, TX, USA), ATIIR1 (1:200; 
cat# sc-1173, Santa Cruz Biotechnology), ATIIR2 (1:200; cat# 
ab92445, Abcam, Cambridge, MA, USA), and β-actin (1:1000; 
cat# ab82618, Abcam). Appropriate secondary antibodies used 
were goat anti-rabbit horseradish peroxidase (HRP) conjugate 
(1:2000; cat# A16110, Life Technologies), donkey anti-goat HRP 
conjugate (1:5000; cat# ab97120, Abcam), or fluorescent rabbit 
anti mouse Alexa Fluor® 647 rabbit anti-mouse (1:2000; cat# 
A21239, Invitrogen). All primary and secondary antibodies were 
diluted in TBS containing 0.1% Tween-20 and 2% skim-milk 
powder. Detection of the HRP-conjugated secondary antibodies 
was achieved using Clarity™ Western ECL substrate (Bio-Rad). 
All membranes were imaged using the ChemiDoc MP imaging 
system (Bio-Rad).
image analysis
3,3′-Diaminobenzidine IHC- and IF IHC-stained slides were 
viewed and imaged using an Olympus BX53 light microscope 
(Tokyo, Japan) and an Olympus FV1200 confocal laser-scanning 
microscope (Olympus), respectively. All IF IHC-stained images 
were processed with CellSens Dimension 1.11 software using the 
2D deconvolution algorithm (Olympus).
resUlTs
histochemical and 3,3′-Diaminobenzidine 
immunohistochemical staining
Hematoxylin and eosin staining confirmed the histological grade 
and the presence of MDBMSCC (n = 6) for each sample. DAB 
IHC staining showed cytoplasmic expression of PRR (Figure 1A, 
brown) localized predominantly to cells within the tumor nests 
(Figure  1A, brown, short arrows). There was also faint immu-
noreactivity in the endothelium of the microvessels (Figure 1A, 
brown, arrowheads) and stronger cytoplasmic staining in cells 
within the peri-tumoral stroma (Figure 1A, brown, long arrows). 
ACE (Figure 1B, brown) was expressed on the endothelium of 
the microvessels, which were predominantly located around the 
periphery of the peri-tumoral stroma. ATIIR1 (Figure 1C, brown) 
was expressed predominantly in the cytoplasm and nuclei of cells 
within the tumor nests (Figure  1C, brown, short arrows) with 
faint cytoplasmic staining in cells within the peri-tumoral stroma 
(Figure 1C, brown, long arrows). Faint cytoplasmic and stronger 
nuclear staining of ATIIR2 (Figure 1D, brown) was observed in 
cells within the tumor nests (Figure 1D, brown, short arrows) and 
some cells within the peri-tumoral stroma (Figure 1D, brown, 
long arrows).
Positive controls for PRR, ACE, ATIIR1, and ATIIR2 
demonstrated the expected staining patterns in human pla-
centa (Image S1A in Supplementary Material, brown), liver 
(Image S1B in Supplementary Material, brown), liver (Image S1C 
in Supplementary Material, brown), and kidney (Image S1D in 
Supplementary Material, brown), respectively. The omission of 
the primary antibody in MDBMSCC samples provided an appro-
priate negative control (Image S1E in Supplementary Material, 
brown).
immunofluorescent immunohistochemical 
staining
We have recently demonstrated the presence, within MDBMSCC, 
of an EMA+/SOX2+/SALL4+/OCT4+/pSTAT3+/NANOG+ CSC 
subpopulation within the tumor nests; an EMA−/SOX2+/OCT4+/
pSTAT3+/NANOG+ CSC subpopulation within the peri-tumor 
stroma; and an EMA−/CD34+/SOX2+/OCT4+/pSTAT3+/NANOG+ 
CSC subpopulation localized to the endothelium of the microves-
sels within the peri-tumoral stroma (16). To investigate if the 
FigUre 1 | representative DaB ihc-stained sections of moderately differentiated buccal mucosal squamous cell carcinoma demonstrating 
cytoplasmic expression of Prr [(a), brown] by cells within the tumor nests (short arrows) and faint staining of endothelium (arrowheads) of the 
microvessels and peri-tumoral stroma (long arrows). ACE [(B), brown] was expressed by the endothelium of the microvessels within the stroma. Strong 
cytoplasmic and nuclear expression of ATIIR1 [(c), brown] was demonstrated in cells within the tumor nests (short arrows), with faint staining in cells within the 
peri-tumoral stroma (long arrows). Strong nuclear and faint cytoplasmic expression of ATIIR2 [(D), brown] was demonstrated in cells within the tumor nests (short 
arrows) and some cells in the peri-tumoral stroma (long arrows). Nuclei were counterstained with hematoxylin [(a–D), blue]. Original magnification: 400×.
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components of the RAS were expressed by one or more of these 
CSC subpopulations, we performed double IF IHC staining to 
investigate the expression patterns of PRR, ACE, ATIIR1, and 
ATIIR2.
(Pro)renin receptor (Figures 2A–C, red) was expressed by the 
EMA+ (Figure 2A, green) cells within the tumor nests, as well as 
the CD34+ endothelium (Figure 2B, green, arrows) and the outer 
pericyte layer (Figure 2B, red, arrowheads) of the microvessels 
and OCT4+ (Figure  2C, green) cells within the peri-tumoral 
stroma (16). ACE (Figure 2D, green, arrows) was expressed on 
the endothelium of the microvessels within the peri-tumoral 
stroma, which expressed SOX2 (Figure 2D, red), distinct from 
the tumor nests. Cytoplasmic expression of ATIIR1 (Figure 2E, 
green) was demonstrated on cells within the tumor nests and the 
endothelium of the microvessels within the peri-tumoral stroma 
expressing PRR (Figure 2E, red). ATIIR2 (Figures 2F,G, red) was 
expressed by cells within the tumor nests that have been shown to 
express SALL4 (Figure 2F, green) (16). Interestingly, cells within 
the peri-tumoral stroma that express OCT4 (16) also expressed 
ATIIR2 (Figure 2G, green). Separated IF IHC-stained images of 
Figure 2 are presented in Image S2 in Supplementary Material.
Western Blotting
Western Blot analysis confirmed the presence of PRR (Figure 3A) 
and ATIIR1 (Figure 3B) within the extracts of all five MDBMSCC 
samples from the original cohort of patients used for DAB IHC 
staining, at their expected molecular weight of 39 and 43 kDa, 
respectively. ACE (Figure 3C) was detected in only one of the 
five MDMBSCC samples analyzed, at the expected molecular 
weight of 195 kDa. High image exposure was required to clearly 
visualize the ACE signal in the MDMBSCC sample, which 
implies that ACE was present at very low abundance. ATIIR2 was 
detected in all five MDBMSCC samples at approximately 51 kDa 
(Figure 3D), which is larger than the native form of the protein 
and may signify detection of a glycosylated isoform. A band at 
approximately 41 kDa was detected in one of the five total protein 
extracts (Figure 3D, BMSCC_3) that may correspond to the native 
protein (27). Detection of β-actin confirmed approximately equal 
total protein loading across all five samples (Figure 3E).
nanostring gene analysis
NanoString gene analysis of the components of the RAS: PRR, 
ACE, ATIIR1, and ATIIR2, was performed in five samples of 
MDBMSCC from the original cohort of six patients used for 
DAB IHC staining, normalized against the housekeeping gene, 
GUSB. Transcriptional profiling confirmed the presence of PRR 
and ACE mRNA in all five samples and ATIIR1 in one sample, 
but ATIIR2 mRNA was below the detectable level within all five 
samples (Figure 4).
DiscUssiOn
The novel finding of the expression pattern of PRR, ATIIR1, 
ATIIR2, and ACE on CSC subpopulations within MDBMSCC 
provides insights into the biology of this aggressive tumor. It is 
noteworthy that the CSC subpopulation within the peri-tumoral 
FigUre 2 | representative immunofluorescent immunohistochemical-stained sections of moderately differentiated buccal mucosal squamous cell 
carcinoma demonstrating Prr [(a), red] was expressed by cells within the tumor nests that stained positively for eMa [(a), green]. PRR [(B), red] was 
also expressed by the CD34+ [(B), green] endothelium of the microvessels. In addition, RRR [(c), red] was expressed by cells within the peri-tumoral stroma, which 
also expressed OCT4 [(c), green]. ACE [(D), green] was expressed on the endothelium of the microvessels, which also expressed SOX2 [(D), red], within the 
peri-tumoral stroma. Cytoplasmic expression of ATIIR1 [(e), green] and PRR [(e), red] was demonstrated in cells within the tumor nests, the peri-tumoral stroma, 
and the endothelium of the microvessels within the peri-tumoral stroma. ATIIR2 [(F,g), red] was expressed by cells within the tumor nests that expressed SALL4 
[(F), green] and OCT4 [(g), green]. Cell nuclei were counterstained with 4′,6′-diamidino-2-phenylindole [(a–g), blue]. Scale bars: 20 μm.
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FigUre 4 | relative expression of mrna transcripts of the 
components of the renin–angiotensin system in five moderately 
differentiated buccal mucosal squamous cell carcinoma samples. 
Expression is depicted in relative units (RU) as a ratio to the GUSB 
housekeeper. Transcriptional profiling confirmed the presence of PRR and 
ACE mRNA in all five samples and ATIIR1 in one sample, but ATIIR2 mRNA 
was below the detectable level within all five samples.
FigUre 3 | Western Blot images of 1De separated moderately differentiated buccal mucosal squamous cell carcinoma total protein extracts probed 
for Prr (a), aTiir1 (B), ace (c), aTiir2 (D), and detected with hrP conjugated goat anti-rabbit (a,B,D) or donkey anti-goat (c), or rabbit anti-rabbit 
(e) secondary antibody. β-actin (e) was used as the loading control and detected using Alexafluor® 647 rabbit anti-mouse secondary antibody.
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stroma does not express EMA. This CSC subpopulation may rep-
resent a “normal” stem cell population or cells that have under-
gone an epithelial to mesenchymal transition (EMT) (28), with 
the endothelial population possibly reflecting the phenomenon 
of vascular mimicry (29).
It is intriguing that although IHC staining demonstrated the 
expression of both ATIIR1 and ATIIR2, supported by WB detec-
tion of bands at the expected size, mRNA expression for ATIIR2 
was not detected. This may be due to rapid degradation of mRNA 
of this protein.
Recent literature suggests that the RAS may play a role in 
cancer growth and metastasis, especially in promoting cell 
proliferation and angiogenesis (25, 30), with a review high-
lighting a role for the RAS in other cancers, predominantly in 
cellular proliferation (28). We have demonstrated an interesting 
expression pattern, within MDBMSCC; the components of the 
RAS on the CSC subpopulations within the tumor nests, peri-
tumoral stroma, and the endothelium of the microvessels within 
the peri-tumoral stroma.
The expression of the ESC marker SOX2 on the endothe-
lium adjacent to the tumor nests is consistent with our recent 
publication demonstrating expression of the stem cell markers 
SALL4 and OCT4 (16). These findings and the observation of the 
expression of PRR and ACE on the endothelium is intriguing and 
may reflect a primitive phenotypic endothelium similar to that 
reported in colorectal cancer (29), although this remains a topic 
for future investigation.
While the analysis of normal buccal mucosa would strengthen 
the interpretation of our data, these novel findings of the localiza-
tion of the components of the RAS to the CSC subpopulations 
within MDBMSCC mirror our similar finding within OTSCC 
(17, 31). Although we have not demonstrated the functionality 
of these receptors in this report, it is exciting to speculate CSCs 
as a potential novel therapeutic target by modulation of the RAS 
using existing anti-hypertensive drugs, such as aliskiren, which 
targets renin; β-blockers, which block the production of (pro)
renin and so decrease levels of renin; ACE inhibitors and ATII 
receptor blockers (32–35).
The relatively small sample numbers and the lack of functional 
data for these receptors in this report are limitations of the study 
and demonstrate the need for further work to better understand 
the precise regulatory function of the RAS on the CSC subpopula-
tions, which may lead to an effective treatment for BMSCC and 
other cancers.
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TaKe hOMe Messages
 1. The components of the RAS: PRR, ACE, ATIIR1, and ATIIR2 
are expressed by MDBMSCC.
 2. PRR is localized to the CSC subpopulations within the tumor 
nests, the peri-tumoral stroma, and the endothelium of the 
microvessels within the peri-tumoral stroma, between the 
tumor nests.
 3. ATIIR1 and ATIIR2 are localized to the CSC subpopulations 
within the tumor nests and the peri-tumoral stroma.
 4. ACE is localized to the endothelium of the microvessels within 
the peri-tumoral stroma.
 5. These novel findings suggest CSCs within this tumor as a 
potential therapeutic target by modulating the RAS.
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iMage s1 | representative DaB ihc-stained sections of positive control 
human tissues showing positive staining for Prr in human placenta (a); 
and ace (B), aTiir1 (c), and aTiir2 (D) in liver. A MDBMSCC sample was 
used as negative control by the omission of the primary antibody (e). Cell nuclei 
were counterstained with hematoxylin [(a–e), blue]. Original magnification: 400×.
iMage s2 | split iF ihc images of Figure 2 demonstrating expression of 
Prr [(a), red] and eMa [(B), green]; Prr [(c), red] and cD34 [(D), green]; 
Prr [(e), red] and OcT4 [(F), green]; sOX2 [(g), red] and ace [(h), green]; 
Prr [(i) red] and aTiir1 [(J), green]; sall4 [(K), green] and aiiTr2 [(l), red]; 
OcT4 [(M), green] and aiiTr2 [(l), red]. Cell nuclei were counterstained with 
4′,6′-diamidino-2-phenylindole [(a–n), blue]. Scale bars: 20 μm.
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